Objectives: ABI-0043 is a novel benzoxazinorifamycin derivative, which derives its potent bactericidal activity by the specific inhibition of bacterial RNA polymerase. We evaluated the in vitro pharmacodynamics and bactericidal activity of ABI-0043 against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA).
Introduction
ABI-0043 is a novel benzoxazinorifamycin that derives its potent bactericidal activity by the specific inhibition of bacterial RNA polymerase. 1,2 ABI-0043 is closely related to rifalazil, also referred to as KRM-1648 or ABI-1648, but displays more potent in vitro activity against Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Propionibacterium acnes and Chlamydia spp. and has improved activity against rifampicin-resistant isolates of S. aureus and S. pyogenes. 2 -4 ABI-0043 has displayed efficacy against S. aureus in several animal models including the neutropenic murine thigh model, 3 the mouse septicaemia model 3 and a foreign body infection model. 5 Limited data exist on the pharmacodynamics and bactericidal activity of ABI-0043 against clinical S. aureus isolates.
Materials and methods
Clinical isolates utilized in the study included methicillin-resistant S. aureus (MRSA; S285 and S293) and methicillin-susceptible S. aureus (MSSA; S288 and S290). All isolates were obtained from the blood of infected patients from the VA Medical Center (Buffalo, NY, USA) and were susceptible to rifampicin. S. aureus ATCC 29213 was utilized as a control. ABI-0043 was provided by Activbiotics Inc., Lexington, MA, USA. ABI-0043 powder was dissolved in 100% dimethyl sulphoxide (DMSO) (Sigma Chemical Company, St Louis, MO, USA) by bath sonication for 30 min to prepare a stock solution of 50 mg/mL. One volume of stock solution was added to four volumes of diluted liquid fill, 3 resulting in a dosing solution containing ABI-0043 in 20% DMSO. The 20% DMSO diluent alone showed no antibacterial effect on S. aureus. 3, 5 Fresh working solutions of ABI-0043 were made prior to each experimental run.
MICs and minimum bactericidal concentrations (MBCs) were determined in quadruplicate using a microdilution technique in accordance with CLSI criteria. 6 Mueller -Hinton broth (Difco Laboratories, Detroit, MI, USA) supplemented with calcium (25 mg/L) and magnesium (12.5 mg/L) (SMHB) was used for all broth microdilution susceptibility testing and selective time-kill experiments. The bactericidal activity of ABI-0043 was assessed by time-kill experiments. Briefly, fresh bacterial colonies from an overnight growth were added to normal saline and adjusted spectrophotometrically to provide a standard suspension. This suspension was diluted with SMHB and a standard antibiotic stock solution to achieve a starting inoculum of $10 6 cfu/mL. Each 10 mL culture was placed in test tubes that were incubated in a water bath at 358C with constant shaking, and 0.1 mL samples were withdrawn for determination of bacterial counts at 0, 1, 2, 4, 8 and 24 h. The following time-kill experiments were evaluated: growth control and 0.5Â, 2Â, 8Â, 16Â, 64Â and 128Â MIC of ABI-0043. Colony counts were determined by plating 50 mL of each diluted sample onto Trypticase soy agar [TSA; with 5% sheep blood (Becton-Dickinson, Sparks, MD, USA)] with an automated spiral dispenser (WASP; Don Whitley Scientific Limited, West Yorkshire, UK) and incubated at 358C to confirm colony counts. This method results in a lower limit of detection of 2.0 log 10 cfu/mL. Antimicrobial carryover was minimized by serial dilution (10-to 100 000-fold) and centrifuging the bacterial samples at 10 000 g for 5 min and reconstituting with sterile normal saline to their original volumes. All time-kill experiments were completed in duplicate to quadruplicate. Development of resistance was evaluated at 24 h for all experiments in duplicate. Samples from each time point were plated on TSA plates containing 4-and 8-fold the MIC of the respective antibiotic to assess the development of resistance and examined for growth after 48 h of incubation at 358C. Bactericidal activity was defined as a reduction of !3 log 10 cfu/mL (99.9% killing) in bacterial density from the starting inoculum.
To accommodate all available data generated for each regimen tested and avoid conclusions based on cfu counts at a single time point, an integrated pharmacokinetic/pharmacodynamic area measure (log ratio area) was applied to all cfu data. For each regimen tested, the area under the cfu versus time curve from 0 to 24 h (AUCcfu 0 -24 ) was calculated via the trapezoidal rule for both the growth control (AUCcfu growth control ) and drug-containing regimens (AUCcfu drug ). The AUCcfu 0 -24 was normalized by the AUCcfu 0 -24 of the growth control and the logarithm of this ratio was used to quantify the drug effect as shown in Equation (1) . Additionally, the traditional approach (log ratio change) of comparing the changes in cfu/mL from 0 h (cfu 0 ) versus 24 h (cfu 24 ) was calculated as shown in Equation (2) .
log ratio change ¼ log 10 ðcfu 24 =cfu 0 Þ ð 2Þ
Using non-linear regression, a four-parameter concentrationeffect Hill-type model was fitted to the effect parameter Systat (Version 11, Richmond, VA, USA) using:
Where the dependent variable (E) is either log ratio area or log ratio change, E 0 the measured effect at zero drug concentration, E max the maximal effect, C:MIC the concentration of drug divided by the MIC, EC 50 the C:MIC for which there is 50% maximal effect and H the Hill or sigmoidicity constant.
Results
ABI-0043 displayed MICs and MBCs against all MRSA and MSSA isolates of 0.008 mg/L. The activity of ABI-0043 is depicted in Figure 1 . At concentrations of 2Â and 4Â MIC, ABI-0043 displayed bacteriostatic activity, with a reduction in bacterial counts at 24 h of ,3 log 10 cfu/mL when compared with the starting inoculum against both MRSA and MSSA. Bactericidal activity was achieved within 4 h at concentrations !16Â MIC against all isolates and was generally maintained through 8 h. However, against S293 and S288 isolates, a rebound in bacterial growth was observed at 24 h. With increasing ABI-0043 concentrations, a concentration-dependent trend towards greater bacterial killing was observed. Bacterial reductions were greatest at higher concentrations of 64Â and 128Â MIC against MRSA and MSSA isolates: a rapid reduction in bacterial counts .4 log 10 cfu/mL was observed as early as 2 h, reaching undetectable limits, which was sustained throughout 24 h. Growth on resistance plates at 4Â MIC was detected at concentrations 0.5Â MIC against S285, S288, S290 and S293 providing a potential explanation for the regrowth that was demonstrated in time -kill experiments. Concentrations !2Â MIC suppressed the development of resistance as no growth was detected on medium containing 4Â or 8Â MIC of drug. Analysis of pharmacodynamics revealed excellent model fits of the data to the Hill model ( Table 1 and Figure 1 ). R 2 values were slightly higher using the log ratio area approach, as all model fits were .0.99 versus .0.96 for the log ratio change approach. Bactericidal activity for ABI-0043 occurred in a concentration-dependent manner, as seen with the steep sigmoidicity constant (H) and low EC 50 against all isolates. Rapid concentration-dependent activity was most evident against MRSA S285, displaying the steepest H among all isolates and a low EC 50 . ABI-0043 against MSSA 288 displayed the shallowest H and highest EC 50 , partially explained by the different concentration-killing profiles, with slight regrowth and less activity at 16Â MIC, versus other isolates where this exposure resulted in bactericidal activity. The maximal effect for ABI-0043 was a .7 log 10 reduction in cfu/mL and a reduction of .4 log 10 of area for ABI-0043 against all isolates.
Discussion
ABI-0043 is a representative of the most recent series of benzoxazinorifamycins, which displays potent activity against S. aureus, including rifampicin-resistant isolates. ABI-0043 is one of a number of rifamycins, such as ABI-0369, ABI-0699 and rifalazil, which also displays extremely low MICs for staphylococci. 2, 3, 7, 8 Although rifampicin, the oldest representative Pharmacodynamics of ABI-0043 rifamycin, possesses rapid concentration-dependent activity against staphylococci, its therapeutic use has been limited due to the rapid emergence of resistant organisms, poor tolerance and interactions with CYP3A4. 9 Rifampicin has typically been utilized in combination with other agents in persistent, difficult-to-treat infections to overcome a high bacterial burden.
However, numerous reports on the emergence of resistance, questionable efficacy and clinical failure raise uncertainty regarding its utility, especially in the treatment S. aureus endocarditis where it has been used in combination with other agents. 10, 11 ABI-0043 possesses more potent activity than rifampicin in vitro and retains some activity against rifampicin-resistant strains. 2, 3 Comparable efficacy has also been established for ABI-0043 at lower doses than rifampicin in murine models of infection, and ABI-0043 has also displayed efficacy equivalent to rifampicin in combination, in an experimental model of foreign body infection. 3 -5 In addition, ABI-0043 does not induce the P450 system, whereas rifampicin is a strong inducer of CYP3A4 and other P450 isoenzymes. 7 In the present study, ABI-0043 displayed rapid bactericidal activity against clinical isolates of S. aureus, at concentrations as low as 16Â MIC. Concentrations above the MIC prevented the amplification of resistant mutants, although exposure to 0.5Â MIC resulted in the development of resistance at 24 h. The pharmacodynamics of ABI-0043 were well described by a Hill-type sigmoidal, maximal effect model, displaying concentrationdependent activity against both MRSA and MSSA, where maximal effect (.7 log 10 cfu/mL) was achieved at higher thresholds of !64Â MIC. Our findings are also similar to other investigations in which ABI-0043 demonstrated a dosedependent response with a high correlation to bacterial kill in a murine pneumococcal pneumonia model. 4 Additionally, the pharmacokinetic profile of ABI-0043 is reported to have a prolonged terminal-phase half-life in animal studies, which may be consistent with once daily dosing in humans. 7, 12 In conclusion, ABI-0043 is a novel rifamycin that may provide an alternative option for the treatment of MRSA infections. Further pharmacokinetic and pharmacodynamic, resistance and clinical studies are warranted to determine its ultimate place in antibacterial therapy. 
